One year after the COVID-19 disease pandemic, the global effort to develop and distribute an effective vaccine has already produced several promising options. Several countries have produced Corona Vaccines but they are facing challenges in Vaccination. The vaccine is a special kind of medicine. Which prepares or protects a person to fight against any disease. Vaccines help to strengthen white blood cells which definitely improves immunity.
To end this pandemic, a large part of the world must be immune to the virus. The safest way to do this is with a vaccine. Vaccines are a technology that humanity has relied on many times in the past to reduce the number of deaths from infectious diseases.
In less than 12 months after the COVID-19 pandemic, several research teams took up the challenge and developed vaccines. Which protects against SARS-CoV-2, the virus that causes COVID-19. Clinical trial data of a one-dose Ad5-nCoV vaccine Independent Data Monitoring Committee shows 65.7% efficacy at preventing symptomatic cases and 90.98% at preventing severe disease.
leading COVID-19 Vaccine developers
Several Corona vaccines have been approved for general or emergency use. Countries such as China, Russia, the United Kingdom, and the United States are among them. So far February 2021, more than 100 million doses had been administered worldwide. A vaccine from Pfizer and BioNTech was also licensed by regulatory agencies in dozens of countries after similarly promising results. Johnson & Johnson’s vaccine is expected to be the next to enter the US market. The company has already applied for an emergency clearance in February 2021. Beijing also approved four of its candidates, several of which are being used by other countries. Russia approved two vaccines before testing them in large trials one of these is distributed in a dozen other countries.
In addition, countries around the world have approved a vaccine from the University of Oxford in the United Kingdom and the British Swedish company AstraZeneca that is cheaper and easier to store and transport than others. About 175 potential Corona Vaccines are in preclinical development by pharmaceutical companies, academic institutions, and government agencies.
Several countries, such as Bahrain and the United Arab Emirates, are making rapid progress in immunizing their citizens. While the vast majority have vaccinated only a small portion of their population or have not yet started. Abu Dhabi and Bahrain are using the vaccine developed by China’s Sinopharm. While parts of the United Arab Emirates are using the vaccine of Pfizer and BioNTech.
Challenges and difficulties
The challenge now is to make these vaccines available to people around the world. The Cost of Vaccines is also a challenge for small and poor countries. It will be important that people in all countries, not just rich countries, have the protection they need. Several countries, most of the wealthy ones, have already reserved almost four billion doses of vaccines. Further, they and have options for another five billion, at current prices.
if the vaccine is not affordable for these nations would be morally wrong. Because, as infectious disease researchers often say, an outbreak anywhere is an outbreak everywhere.
Since most of the vaccine doses need to be stored at temperatures below -70 to -80 degrees Celsius. Only short distances are key to preventing spoilage during transit. Transportation and the safe delivery of the Vaccine is yet another challenge. But productive challenges, vaccine nationalism, and new strains of the virus are all obstacles.
The World Health Organization (WHO) and other multilateral institutions like the World Bank are focusing on finance and manufacturing COVID-19 vaccine for global use, in particular, to ensure fair distribution among all countries. Coalition for Epidemic Preparedness Innovations (CEPI), the UK-based Wellcome Trust, and the World Economic Forum. Gavi, the Vaccine Alliance, founded by the Gates Foundation, is a public-private partnership focusing on improving access to Corona vaccine for low-income countries.